Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus TRIACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus TRIACORT.
FLOVENT DISKUS 250 vs TRIACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Adrenocorticosteroid; binds to glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and metabolic effects.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
10-20 mg orally once daily
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
2-3 h. The terminal elimination half-life is short, requiring thrice-daily dosing for sustained effect. Context: In patients with hepatic impairment, half-life may be prolonged up to 4-5 h.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Primarily hepatic metabolism (>90%) with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces). Less than 5% of the parent drug is excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid